医疗技术公司Kestra Medical Technologies Inc（KMTS）今日盘后股价大跌6.05%，主要原因是公司公布的季度财报显示亏损远超分析师预期。
根据公司发布的财报，截至4月30日的季度中，Kestra Medical Technologies调整后每股亏损高达2.21美元，远远超过华尔街分析师平均预期的0.52美元亏损。公司本季度净亏损达到5440万美元，这一结果令投资者感到失望。尽管如此，公司营收表现较为亮眼，达到1723万美元，超过分析师预期的1575万美元。
尽管季度业绩不佳导致股价下跌，但华尔街分析师对Kestra Medical Technologies的长期前景仍保持谨慎乐观。目前，分析师对该公司股票的平均评级为"买入"，其中包括5个"强烈买入"或"买入"评级，1个"持有"评级，没有"卖出"或"强烈卖出"评级。分析师给出的12个月目标价中位数为28.00美元，较最新收盘价15.43美元高出约44.9%，显示出对公司未来发展的信心。然而，投资者仍需密切关注公司未来的盈利能力改善情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.